Robert Babak Faryabi, PhD, describes the use of artificial intelligence at the Penn Center for Precision Medicine to develop algorithms to detect and interpret the effects of complex mutations in the cancer genome for patients with acute myeloid leukemia. This information is used to determine which patients will most benefit from specific targeted immunotherapies for the disease. Dr. Faryabi is an Assistant Professor of Pathology and Laboratory Medicine at Penn Medicine.
Published
February 13, 2018
Created by
BROADCASTMED